p53 status: An indicator for the effect of preoperative radiotherapy of rectal cancer

Radiotherapy and Oncology

Volumn 51, Issue 2, 1999, Pages 169-174

  Adell, Gunnar ^a   Sun, Xiao Feng ^a   Stål, Olle ^a   Klintenberg, Claes ^a   Sjödahl, Rune ^a   Nordenskjöld, Bo ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Local failure; P53; Radiotherapy; Rectal carcinoma

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033062893     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(99)00041-9     Document Type: Article

References (30)

1. Arbman G., Nilsson E., Hallböök O., Sjödahl R. Local recurrence following total mesorectal excision for rectal cancer. Br. J. Surg. 83:1996;375-379.
2. Auvinen A., Isola J., Visakorpi T., Koivula T., Virtanen S., Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br. J. Cancer. 70:1994;293-296.
3. Awwad S., Jaros E., Somes J., Lunec J. p53 overexpression in head and neck carcinoma and radiotherapy results. Int. J. Radiat. Oncol. Biol. Phys. 34:1996;323-332.
4. Bartek J., Bartkova J., Vojtesek B., et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 6:1991;1699-1703.
5. Benhattar J., Cerottini J.P., Saraga E., Metthez G. Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer. 69:1996;190-192.
6. Campo E., de la Calle-Martin O., Miquel R., et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinoma. Cancer Res. 51:1991;4436-4442.
7. Cox D.R. Regression models and life tables. J. R. Statist. Soc. B. 34:1972;187-220.
8. Cunningham J., Lust J., Schaid D., et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res. 52:1992;1974-1980.
9. Desai G., Myerson R., Higashikubo R., et al. Carcinoma of the rectum. Possible cellular predictor of metastatic potential and response to radiation therapy. Dis. Colon Rectum. 39:1996;1090-1096.
10. Fearon E., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
11. Fu C-G., Tominaga O., Nagawa H., et al. Role of p53 and p21/WAF 1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis. Colon Rectum. 41:1998;68-74.
12. Gordon N., Dawson A., Bennett B., Innes G., Eremin O., Jones P. Outcome in colorectal adenocarcinoma: two seven-year studies of a population. Br. Med. J. 307:1993;707-710.
13. Hamelin R., Laurent-Puig P., Olschwang S., et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 106:1994;42-48.
14. Heald R., Ryall R. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet, i:1986;1479-1482.
15. Jahnson S., Risberg B., Karlsson M., Westman G., Bergström R., Pedersen J. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur. Urol. 28:1995;135-142.
16. Jansson T., Inganäs M., Sjögren S., et al. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J. Clin. Oncol. 13:1995;2745-2751.
17. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc. 53:1958;457-481.
18. Lane D. P53, guardian of the genome. Nature. 358:1992;15-16.
19. Langendijk J., Thunnissen F., Lamers R., de Jong J., ten Velde G., Wouters E. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother. Oncol. 36:1995;218-224.
20. McIlwrath A., Vasey P., Ross G., Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 54:1994;3718-3722.
21. O'Connor O., Jackman J., Jondle D., Bhatia K., Magrath I., Kohn K. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res. 53:1993;4776-4780.
22. Prendergast N., Atkins M., Schatter E., Paulson D., Walther P. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J. Urol. 155:1996;1685-1692.
23. Purdie C., O'Grady J., Piris J., Wyllie A., Bird C. p53 expression in colorectal tumours. Am. J. Pathol. 138:1991;807-813.
24. Ross P., Cunningham D. Adjuvant treatment of colorectal cancer. Oncology Today. 14:1996;7-11.
25. Sasaki K., Sato T., Kurose A., Ikeda E. Immunohistochemical detection of p21 and p53 proteins in formalin fixed, paraffin-embedded tissue sections of colorectal carcinoma. Hum. Pathol. 27:1996;912-916.
26. Sjögren S., Inganäs M., Norberg T., et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 88:1996;173-182.
27. Stål O., Stenmark-Askmalm M., Wingren S., et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol. 34:1995;767-770.
28. Sun X-F., Carstensen J., Zhang H., Arbman G., Nordenskjöld B. Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur. J. Cancer. 32A:1996;1963-1967.
29. Swedish Rectal Cancer Trial, Improved survival with preoperative radiotherapy in resectable rectal cancer, N. Engl. J. Med., 1997;336:980-987.
30. Wilson G., Richman P., Dische S., et al. p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br. J. Cancer. 71:1995;1248-1252.